These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1010 related items for PubMed ID: 16627581
1. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Yamamoto Y, Udagawa N, Matsuura S, Nakamichi Y, Horiuchi H, Hosoya A, Nakamura M, Ozawa H, Takaoka K, Penninger JM, Noguchi T, Takahashi N. Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581 [Abstract] [Full Text] [Related]
2. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T. Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921 [Abstract] [Full Text] [Related]
3. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT. J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342 [Abstract] [Full Text] [Related]
4. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP. J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [Abstract] [Full Text] [Related]
5. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT, Martin TJ, Nagai K, Suda T. Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286 [Abstract] [Full Text] [Related]
6. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644 [Abstract] [Full Text] [Related]
7. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. Ikeda T, Utsuyama M, Hirokawa K. J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864 [Abstract] [Full Text] [Related]
8. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T, Takato T, Nakamura K, Kawaguchi H. J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804 [Abstract] [Full Text] [Related]
9. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T. J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996 [Abstract] [Full Text] [Related]
10. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N. Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574 [Abstract] [Full Text] [Related]
11. PTH differentially regulates expression of RANKL and OPG. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA. J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393 [Abstract] [Full Text] [Related]
12. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. Cao J, Venton L, Sakata T, Halloran BP. J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404 [Abstract] [Full Text] [Related]
13. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. Notoya M, Otsuka E, Yamaguchi A, Hagiwara H. Biochem Biophys Res Commun; 2004 Nov 12; 324(2):655-60. PubMed ID: 15474477 [Abstract] [Full Text] [Related]
14. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. Biochem Biophys Res Commun; 2000 Sep 07; 275(3):768-75. PubMed ID: 10973797 [Abstract] [Full Text] [Related]
15. Breast cancer cells interact with osteoblasts to support osteoclast formation. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. Endocrinology; 1999 Oct 07; 140(10):4451-8. PubMed ID: 10499498 [Abstract] [Full Text] [Related]
16. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. Suda K, Udagawa N, Sato N, Takami M, Itoh K, Woo JT, Takahashi N, Nagai K. J Immunol; 2004 Feb 15; 172(4):2504-10. PubMed ID: 14764723 [Abstract] [Full Text] [Related]
17. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Ishii T, Ohshima S, Ishida T, Mima T, Tabunoki Y, Kobayashi H, Maeda M, Uede T, Liaw L, Kinoshita N, Kawase I, Saeki Y. Biochem Biophys Res Commun; 2004 Apr 09; 316(3):809-15. PubMed ID: 15033472 [Abstract] [Full Text] [Related]
18. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. Lossdörfer S, Schwartz Z, Wang L, Lohmann CH, Turner JD, Wieland M, Cochran DL, Boyan BD. J Biomed Mater Res A; 2004 Sep 01; 70(3):361-9. PubMed ID: 15293309 [Abstract] [Full Text] [Related]